Systemic Evaluation of the Effect of Diabetes Mellitus on Breast Cancer in a Mouse Model

2Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Breast cancer complicated with diabetes mellitus (DM) is a common disease. To evaluate the effect of preexisting DM on breast cancer progression without drug interference, we used a streptozotocin (STZ)-induced type 2 diabetes mellitus BALB/c mouse model. We found that 4T1 breast cancer complicated with DM decreased the mouse survival time compared with 4T1-bearing mice. The diversity of gut microbiome was affected by DM. The infiltration of mucosal-associated invariant T cell (MAIT), CD8+ T cell, and CD4+ T cell in the tumor was significantly decreased in the DM-4T1 group compared with the 4T1 group. The transcriptome data of tumor tissues indicated that the expressions of inflammatory C–C chemokine- and metabolism-related genes were greatly changed. The abnormal expression of these genes may be related with the decreased T-cell infiltration in DM-4T1. In conclusion, the gut microbiome and tumor microenvironment of diabetic breast cancer patients have unique features. The effect of diabetes on breast cancer should be considered in the treatment for diabetic breast cancer patients.

Cite

CITATION STYLE

APA

Wei, N., Lu, J., Lin, Z., Wang, X., Cai, M., Jiang, S., … Cui, L. (2022). Systemic Evaluation of the Effect of Diabetes Mellitus on Breast Cancer in a Mouse Model. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.829798

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free